Drug Combination Details
| General Information of the Combination (ID: C82816) | |||||
|---|---|---|---|---|---|
| Name | Taxifolin NP Info | + | Sorafenib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | FOXP3 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Sor-Tau combination led to FOXP3 down-regulation in hepatic cancer cells (HepG2) and improved therapeutic efficacy of sorafenib treated HCC. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects. Asian Pac J Cancer Prev. 2019 Oct 1;20(10):3007-3013. | |||
